Group 1 - The company, Easy Health (02661), plans to conduct a global offering of 26.54 million shares from December 15 to December 18, 2025, with a share price of HKD 22.68, and expects trading to commence on December 23, 2025 [1] - Easy Health ranks 10th in China's digital integrated health services and health insurance market based on 2024 revenue, according to a report by Sullivan [1] - The company provides a comprehensive range of health-related services, including early disease screening, health check-ups, medical appointment services, and the sale of health products [1] Group 2 - The company has entered into a cornerstone investment agreement with 澳琴合鸣, which will subscribe for approximately 4.8018 million shares at the offering price, totaling around RMB 100 million [2] - The net proceeds from the global offering are estimated to be approximately HKD 513.4 million, with 40% allocated to enhancing brand awareness and user engagement, 20% for medical and real-world research, 20% for improving AI and big data capabilities, 10% for expanding into more regions and overseas markets, and 10% for working capital and other general corporate purposes [2]

Group 1 - The company plans to conduct a global offering of 26.54 million shares from December 15 to December 18, 2025, with 10% allocated for Hong Kong and 90% for international sales, at a price of HKD 22.68 per share [1] - The shares are expected to start trading on the Hong Kong Stock Exchange on December 23, 2025 [1] - According to a report by Frost & Sullivan, the company ranks 10th in China's digital integrated health services and health insurance market based on 2024 revenue [1] Group 2 - The net proceeds from the global offering, assuming the over-allotment option is not exercised, are estimated to be approximately HKD 513.4 million [2] - The company intends to allocate approximately 40% of the proceeds to enhance brand awareness, increase user engagement, and strengthen partnerships [2] - About 20% of the proceeds will be used for medical research and real-world studies, another 20% for improving capabilities in AI and big data, 10% for expansion into more regions and overseas markets, and 10% for working capital and other general corporate purposes [2]

Group 1 - The company, Easy Health (02661), plans to conduct an initial public offering (IPO) from December 15 to December 18, 2025, offering a total of 26.54 million shares at a price of HKD 22.68 per share, with 10% allocated for Hong Kong and 90% for international sales [1] - According to a report by Sullivan, the company ranks 10th in China's digital integrated health services and health insurance market based on 2024 revenue [1] - The company provides a comprehensive range of health-related services, including early disease screening, health check-ups, medical appointment services, and the sale of health products, aiming to offer affordable health solutions [1] Group 2 - The company has entered into a cornerstone investment agreement with 澳琴合鸣, which will subscribe for approximately 4.8018 million shares, totaling around RMB 100 million at the IPO price [2] - The net proceeds from the global offering are estimated to be approximately HKD 513.4 million, with 40% allocated to enhancing brand awareness and user engagement, 20% for medical and real-world research, 20% for improving AI and big data capabilities, 10% for expanding into more regions and overseas markets, and 10% for working capital and general corporate purposes [2]

Core Viewpoint - The leading health technology platform, Qingsong Health Group, has officially passed the hearing for its IPO on the Hong Kong Stock Exchange, aiming to enhance its digital health services and insurance solutions through advanced technology [1][2] Group 1: Company Overview - Qingsong Health Group was established in 2014 and is recognized as a leading digital comprehensive health service and health insurance solution platform in China [1] - According to a report by Sullivan, Qingsong Health Group ranks seventh in China's digital health service market based on projected revenue for 2024 [1] Group 2: Service Offerings - The company provides a diverse range of personalized health services, including insurance products, health screenings, health consultations, medical appointment services, and health product sales, targeting users seeking comprehensive health solutions [1] - Qingsong Health Group leverages AI and other technologies to empower industry participants in creating high-quality health education content [1] Group 3: Technological Development - The company has developed its own AI technology stack, AIcare, which integrates artificial intelligence, big data, and cloud computing capabilities, applied across various business segments such as user services, intelligent risk control, personalized marketing, product innovation, and operational efficiency [1] - Through the continuous optimization of AIcare, Qingsong Health Group has achieved a deep and precise transformation of its health and insurance businesses, setting a new benchmark for "AI + Health" in the industry [1] Group 4: IPO Fund Utilization - The funds raised from the IPO are intended for ongoing research and development, strengthening AI technology infrastructure, expanding the digital health ecosystem, enhancing user experience, and pursuing international expansion to accelerate the realization of the long-term strategic goal of "technology empowering public health" [2]

Core Viewpoint - The company, Easy Health Group, is updating its prospectus for an IPO on the Hong Kong Stock Exchange, with CICC and China Merchants Securities International as joint sponsors [1]. Company Overview - Easy Health Group is a one-stop platform in China focusing on providing digital integrated health services and health insurance solutions. It ranks 10th in the digital integrated health services and health insurance market in China based on projected 2024 revenue [4]. - The company aims to offer accessible, precise, and affordable health solutions to individuals in need, including screening promotion, health checks, medical appointment services, and health product sales [4]. Service Offerings - The company provides a variety of personalized health services targeting users seeking comprehensive health solutions, including screening promotion and consultation services, integrated health service packages, digital marketing (health education), and digital medical research support [4][5][6][7][8]. - Digital marketing services were launched in 2023, offering tailored digital marketing solutions to pharmaceutical companies and charitable foundations, with a significant increase in the number of clients and health education content produced over the years [5]. - The company supports the pharmaceutical industry by providing comprehensive solutions for medical research, including real-world study design and clinical trial data analysis, with a growing number of clients [6]. Financial Performance - The company reported revenues of approximately RMB 490 million in 2023, RMB 945 million in 2024, and projected RMB 656 million for the first half of 2025. The profits for the same periods were RMB 73.62 million, RMB 10.39 million, and RMB 86.05 million respectively [9][10]. - The revenue cost and gross profit margins have shown fluctuations, with gross profit margins of 82.6% in 2022, decreasing to 32.5% by 2025 [10].